Explain the Controversy About the New Sublingual Sufentanil (Dsuvia)

March 2019

You'll hear about a new sublingual sufentanil tablet (Dsuvia, deh-SOO-vee-uh) for acute pain management.

It was initially developed for battlefield use.

But FDA approval of this potent opioid during the opioid epidemic...with its easy-to-administer dosage form...is stirring up concerns.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Geriatrics Use the New Beers Criteria to Evaluate Med Use in Older Adults
Generics Be Ready for New Albuterol HFA and Advair Diskus Generics
Stroke Expect to See TWO Antiplatelets Short-Term After a Minor Stroke or TIA
Diabetes Consider Heart Failure When Weighing Meds for Diabetes
Respiratory & Allergy Ensure Safe Use of Neti Pots and Nasal Irrigation
Muscle Relaxants Advise Caution With Muscle Relaxants
Epinephrine Watch for Differences Between Symjepi and Epinephrine Auto-Injectors
Anticoagulants Optimize Anticoagulants to Reduce Stroke Risk in Atrial Fib Patients
Acne Don't Buy the Hype About New Acne Meds Altreno and Seysara
Tuberculosis Focus on Safety and Adherence With Meds for Latent TB
Diabetes Have a Plan to Manage Diabetes Meds Before and After Surgery
Opioids Explain the Controversy About the New Sublingual Sufentanil (Dsuvia)